Aldeyra Therapeutics
ALDX
24 hedge funds and large institutions have $32.9M invested in Aldeyra Therapeutics in 2015 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
89% more capital invested
Capital invested by funds: $17.4M → $32.9M (+$15.4M)
60% more funds holding
Funds holding: 15 → 24 (+9)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$5.95M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.2M |
| 3 |
PA
Perceptive Advisors
New York
|
+$4.42M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.3M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$356K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$21.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$8.83K |
| 4 |
SIM
Spark Investment Management
New York
|
-$6.04K |
ALDX Hedge Fund Activity: Q2 2015 in Review
24 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2015, worth a combined $32.9M — up 89% from $17.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ALDX positions and 1 closed out — a net gain of 9 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $5.95M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $356K sold.
- 24 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2015, up from 15 in Q1 2015.
- Funds reported $32.9M of Aldeyra Therapeutics stock for Q2 2015, up 89% quarter-over-quarter.
- 10 funds opened new Aldeyra Therapeutics positions in Q2 2015 and 1 closed out, a net change of +9 holders.
- The largest Aldeyra Therapeutics buyer in Q2 2015 was Deerfield Management, an estimated $5.95M added.
- The largest Aldeyra Therapeutics seller in Q2 2015 was DAFNA Capital Management, an estimated $356K sold.
Based on aggregated 13F filings for Q2 2015.